» Articles » PMID: 30593515

Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2018 Dec 30
PMID 30593515
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The purpose of this study is to characterize the mutational landscape across the spectrum of urothelial carcinoma (UC) to identify mutational features and potential therapeutic targets.

Experimental Design: Using targeted exome sequencing ( = 237 genes), we analyzed the mutation spectra of 82 low-grade nonmuscle-invasive bladder cancers (LG-NMIBC), 126 high-grade (HG) NMIBC, 199 muscle-invasive bladder cancers (MIBC), 10 LG-upper tract urothelial cancers (LG-UTUC), and 55 HG-UTUC.

Results: and mutations were significantly more common in LG-NMIBC (72% and 44%, respectively) versus other bladder subtypes. alterations were also enriched in LG-UTUC versus HG-UTUC tumors (80% vs. 16%). In contrast, and mutations were significantly more frequent in all 3 HG urothelial carcinoma subtypes than in LG-NIMBC (45%-58% vs. 4%; 9%-22% vs. 0; respectively). Among LG-NMIBC tumors, mutations were more common in women than in men (71% vs. 38%). HG-NMIBC and MIBC had higher tumor mutational burden (TMB) than LG-NMIBC ( = 0.001 and < 0.01, respectively). DNA-damage repair (DDR) alterations were associated with a higher TMB in HG-NMIBC and MIBC tumors, and these two tumor types were also enriched for an APOBEC mutational signature compared with LG-NMIBC and HG-UTUC. Alterations in , and correlated with worse overall survival in HG-UTUC and occurred concurrently.

Conclusions: Our analysis suggests that a fraction of MIBCs likely arise from precursor lesions other than LG-NMIBC. mutations are twice as common in women with LG-NIMBC than those in men. DDR gene mutations and APOBEC mutagenesis drive mutations in HG-NMIBC and MIBC. UTUC has a distinct mutation profile from bladder cancer.

Citing Articles

Natural history of bladder cancer: Validation of the multiple pathway model in multi-omics era.

Bedore S, Aguilar K, Lokeshwar V Urol Oncol. 2025; 43(2):88-93.

PMID: 39986827 PMC: 11850028. DOI: 10.1016/j.urolonc.2024.10.003.


Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression.

Jin K, Ding Y, Xu J, Liu Z, Zeng H, Su X J Immunother Cancer. 2025; 13(1.

PMID: 39762080 PMC: 11749520. DOI: 10.1136/jitc-2024-010964.


Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.

Lemberger U, Ernhofer B, Krieger S, Bruchbacher A, Oszwald A, Laukhtina E Eur Urol Open Sci. 2024; 71:38-48.

PMID: 39717660 PMC: 11664179. DOI: 10.1016/j.euros.2024.10.022.


Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.

Soltani-Tehrani A, Kumar A, Pohar K Transl Cancer Res. 2024; 13(11):6489-6502.

PMID: 39697728 PMC: 11651738. DOI: 10.21037/tcr-24-180.


The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers.

Antar R, Fawaz C, Gonzalez D, Xu V, Drouaud A, Krastein J Curr Oncol. 2024; 31(11):6909-6937.

PMID: 39590142 PMC: 11593205. DOI: 10.3390/curroncol31110511.